Back to search
FDAFDA · Food and drugs·Recall number D-0554-2023

Tadalafil Tablets, USP 5 mg, 30-count bottles, Rx Only, Repackaged By: Northwind Pharmaceuticals, Indianapolis, IN 46203. NDC 51655-487-52

Published May 3, 2023 · Recall initiated: March 16, 2023

Summary

FDA records drug Class II recall D-0554-2023, published May 3, 2023 and initiated March 16, 2023. Recalling firm: Northwind Pharmaceuticals LLC; Status: Ongoing; Reported quantity: 23 bottles; Lot: Lot #: F114302001, Exp. Date 05/31/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations

What to do

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit

Get an email if TADALAFIL has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
TADALAFIL
Manufacturer
Northwind Pharmaceuticals LLC
Distributor
Nationwide with the United States
Lot
Lot #: F114302001, Exp. Date 05/31/2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Tadalafil Tablets, USP 5 mg, 30-count bottles, Rx Only, Repackaged By: Northwind Pharmaceuticals, Indianapolis, IN 46203. NDC 51655-487-52 recalled?

Yes. FDA published recall D-0554-2023 on May 3, 2023. Reported hazard: CGMP Deviations

What should I do if I have this product?

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: TADALAFIL.